TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07226791: A Phase 2 Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Achievement of Primary Fascial Closure Without the Use

Sponsor: AbbVie · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$6,573,600

Rescue Site Savings

+$4,349,200

Unlock Full NCT07226791 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07226791 Rescue Dossier →